Travere Therapeutics (NASDAQ:TVTX – Get Free Report) and Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Travere Therapeutics and Kalaris Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Travere Therapeutics | 1 | 2 | 10 | 0 | 2.69 |
| Kalaris Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
Travere Therapeutics presently has a consensus target price of $61.67, indicating a potential downside of 6.51%. Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 349.64%. Given Kalaris Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Travere Therapeutics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Travere Therapeutics | $490.73 million | 12.67 | -$25.55 million | ($0.46) | -143.39 |
| Kalaris Therapeutics | N/A | N/A | -$43.44 million | ($2.02) | -2.06 |
Travere Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
66.0% of Kalaris Therapeutics shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Travere Therapeutics and Kalaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Travere Therapeutics | -7.35% | -55.15% | -6.88% |
| Kalaris Therapeutics | N/A | -71.71% | -42.95% |
Volatility & Risk
Travere Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.
About Travere Therapeutics
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Kalaris Therapeutics
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
